EA024194B8 - Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы - Google Patents

Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы

Info

Publication number
EA024194B8
EA024194B8 EA201370166A EA201370166A EA024194B8 EA 024194 B8 EA024194 B8 EA 024194B8 EA 201370166 A EA201370166 A EA 201370166A EA 201370166 A EA201370166 A EA 201370166A EA 024194 B8 EA024194 B8 EA 024194B8
Authority
EA
Eurasian Patent Office
Prior art keywords
tyrosine kinase
kinase inhibitors
containing tyrosine
hydrazide containing
diarylacetylene
Prior art date
Application number
EA201370166A
Other languages
English (en)
Other versions
EA024194B1 (ru
EA201370166A1 (ru
Inventor
Прабал Сенгупта
Хемант Ашвинбхаи Чокши
Четан Сурджитсингх Пури
Саббирхусен Юсуфбхаи Чиманвала
Варун Анилкумар Мехта
Дипали Манубхаи Десаи
Тринадха Рао Читтури
Раджаманнар Тхеннати
Джонатан Дэвид Марк АТКИНСОН
Original Assignee
Сан Фарма Адвансед Ресьорч Компани Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Адвансед Ресьорч Компани Лтд filed Critical Сан Фарма Адвансед Ресьорч Компани Лтд
Publication of EA201370166A1 publication Critical patent/EA201370166A1/ru
Publication of EA024194B1 publication Critical patent/EA024194B1/ru
Publication of EA024194B8 publication Critical patent/EA024194B8/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C241/00Preparation of compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C241/04Preparation of hydrazides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/74Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение относится к новым диарилацетиленгидразидным соединениям формулы (I) или к их фармацевтически приемлемой соли в качестве ингибиторов тирозинкиназ, где Р, Q, R, R, X и Y такие, как в формуле изобретения.
EA201370166A 2011-01-21 2012-01-23 Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы EA024194B8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN184MU2011 2011-01-21
PCT/GB2012/050132 WO2012098416A1 (en) 2011-01-21 2012-01-23 Diarylacetylene hydrazide containing tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
EA201370166A1 EA201370166A1 (ru) 2014-05-30
EA024194B1 EA024194B1 (ru) 2016-08-31
EA024194B8 true EA024194B8 (ru) 2016-11-30

Family

ID=45540888

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370166A EA024194B8 (ru) 2011-01-21 2012-01-23 Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы

Country Status (12)

Country Link
US (1) US9024021B2 (ru)
EP (1) EP2665709B1 (ru)
JP (1) JP5905028B2 (ru)
KR (1) KR101892574B1 (ru)
CN (1) CN103502217B (ru)
AU (1) AU2012208388C1 (ru)
BR (1) BR112013018212B1 (ru)
CA (1) CA2825367C (ru)
EA (1) EA024194B8 (ru)
ES (1) ES2608829T3 (ru)
MX (1) MX336051B (ru)
WO (1) WO2012098416A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134922A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
US9856214B2 (en) * 2013-11-15 2018-01-02 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and their method of use
JP6771491B2 (ja) 2015-05-14 2020-10-21 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー Ebna1阻害剤およびその使用方法
KR20180011772A (ko) * 2015-05-18 2018-02-02 썬 파마 어드밴스트 리서치 컴패니 리미티드 신규 아미도헤테로아릴 아로일 히드라지드 에틴
CA3014740C (en) * 2016-02-16 2021-06-01 Korea Institute Of Science And Technology 2,3,5-substituted thiophene compound as protein kinase inhibitor
EA037697B1 (ru) * 2016-06-02 2021-05-12 Сан Фарма Адвансед Ресёрч Компани Лимитед Лечение болезни паркинсона
SG11201810294QA (en) * 2016-06-02 2018-12-28 Sun Pharma Advanced Res Co Ltd Treatment for parkinson's disease
US11273126B2 (en) 2017-03-15 2022-03-15 Sun Pharma Advanced Research Company Limited Amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[N′-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl) amide
US11351123B2 (en) 2017-03-15 2022-06-07 Sun Pharma Advanced Research Company Limited Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
EP3793546A4 (en) 2018-05-17 2021-12-08 The Wistar Institute CRYSTALLINE FORMS OF EBNA1-INHIBITOR AND METHOD OF MANUFACTURING AND USING THEREOF
CA3142899A1 (en) 2019-06-11 2020-12-17 Sun Pharma Advanced Research Company Ltd. Treatment for synucleinopathies
AU2020412067A1 (en) * 2019-12-26 2022-08-11 Beijing Innocare Pharma Tech Co., Ltd. Crystalline forms of (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide
JP7505719B2 (ja) 2020-02-28 2024-06-25 テグ-キョンプク メディカル イノベーション ファウンデーション 3-((8-((1H-ピラゾール-4-イル)アミノ)イミダゾ[1,2-a]ピリジン-3-イル)エチニル)-N-フェニルベンズアミド誘導体、その調製法、それを活性成分として含有する癌の予防用又は治療用医薬組成物
JP2023536440A (ja) 2020-07-31 2023-08-25 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド アルツハイマー病の治療のためのn’-(2-クロロ-6-メチルベンゾイル)-4-メチル-3-[2-(3-キノリル)エチニル]-ベンゾヒドラジド
TW202317530A (zh) 2021-06-29 2023-05-01 日商住友化學股份有限公司 雜環化合物及含有其之組成物之抗藥性有害節肢動物防除方法
WO2024042483A1 (en) 2022-08-25 2024-02-29 Sun Pharma Advanced Research Company Limited Methods of treating chronic myeloid leukemia using the tyrosine kinase inhibitor vodobatinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314723A1 (en) * 2001-11-27 2003-05-28 Warner-Lambert Company Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
WO2005094822A1 (en) * 2004-03-22 2005-10-13 Eli Lilly And Company Pyridyl derivatives and their use as mglu5 receptor antagonists
WO2007075869A2 (en) * 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
MXPA01010292A (es) 1999-04-15 2002-10-23 Squibb Bristol Myers Co Inhibidores ciclicos de la proteina tirosina cinasa.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2009100536A1 (en) * 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314723A1 (en) * 2001-11-27 2003-05-28 Warner-Lambert Company Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
WO2005094822A1 (en) * 2004-03-22 2005-10-13 Eli Lilly And Company Pyridyl derivatives and their use as mglu5 receptor antagonists
WO2007075869A2 (en) * 2005-12-23 2007-07-05 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds

Also Published As

Publication number Publication date
KR20140016889A (ko) 2014-02-10
AU2012208388C1 (en) 2017-04-27
EP2665709B1 (en) 2016-12-07
WO2012098416A1 (en) 2012-07-26
US9024021B2 (en) 2015-05-05
CA2825367A1 (en) 2012-07-26
JP2014510037A (ja) 2014-04-24
KR101892574B1 (ko) 2018-08-28
CN103502217A (zh) 2014-01-08
CA2825367C (en) 2018-09-25
AU2012208388A1 (en) 2013-08-22
AU2012208388A2 (en) 2013-08-22
MX336051B (es) 2016-01-07
ES2608829T3 (es) 2017-04-17
CN103502217B (zh) 2015-11-25
MX2013008296A (es) 2014-03-21
BR112013018212B1 (pt) 2021-12-14
ES2608829T8 (es) 2017-04-27
EA024194B1 (ru) 2016-08-31
AU2012208388B2 (en) 2017-01-05
BR112013018212A2 (pt) 2020-12-29
JP5905028B2 (ja) 2016-04-20
US20130296557A1 (en) 2013-11-07
EP2665709A1 (en) 2013-11-27
EA201370166A1 (ru) 2014-05-30

Similar Documents

Publication Publication Date Title
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
UA111382C2 (uk) Інгібітори протеїнкінази
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
PH12015500260A1 (en) Neprilysin inhibitors
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MX2019010602A (es) Inhibidores de cdk.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
AU2012250958A8 (en) Amino-pyridine-containing Spleen Tyrosine Kinase (Syk) inhibitors
MY165087A (en) Neprilysin inhibitors
MX2012013197A (es) Inhibidores de indazol de cinasa.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX355088B (es) Inhibidores de tienopirimidina de proteina cinasa c atipica.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
JO3248B1 (ar) عملية لتحضير إنزيمات مثبطة من نوع c-fms
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
IN2015DN00659A (ru)
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors